127 related articles for article (PubMed ID: 38095514)
21. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
22. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway.
Yang Y; Qi J; Hu J; Zhou Y; Zheng J; Deng W; Inam M; Guo J; Xie Y; Li Y; Xu C; Deng W; Chen W
Cancer Lett; 2024 Apr; 588():216765. PubMed ID: 38408604
[TBL] [Abstract][Full Text] [Related]
23. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
24. Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
O'Meara TA; Tolaney SM
Oncotarget; 2021 Mar; 12(5):394-400. PubMed ID: 33747355
[TBL] [Abstract][Full Text] [Related]
25. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
27. Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types.
Asleh K; Ouellette RJ
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398121
[TBL] [Abstract][Full Text] [Related]
28. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.
Huang Y; Liao J; Liang F; Lin P; Wu S; Ye Y; Gao M; Chen R; Zeng H; Yin X; Jiang Y; Ouyang N; Han P; Huang X
Int Immunopharmacol; 2022 Sep; 110():108846. PubMed ID: 35816946
[TBL] [Abstract][Full Text] [Related]
29. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
30. MHC-I genotype and tumor mutational burden predict response to immunotherapy.
Goodman AM; Castro A; Pyke RM; Okamura R; Kato S; Riviere P; Frampton G; Sokol E; Zhang X; Ball ED; Carter H; Kurzrock R
Genome Med; 2020 May; 12(1):45. PubMed ID: 32430031
[TBL] [Abstract][Full Text] [Related]
31. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy.
Gu Y; Zhang Z; Ten Dijke P
Cell Mol Immunol; 2023 Apr; 20(4):318-340. PubMed ID: 36823234
[TBL] [Abstract][Full Text] [Related]
32. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
Jia Q; Wang J; He N; He J; Zhu B
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729
[TBL] [Abstract][Full Text] [Related]
33. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
35. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
37. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
38. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
39. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
Sun S; Xu L; Zhang X; Pang L; Long Z; Deng C; Zhu J; Zhou S; Wan L; Pang B; Xiao Y
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915876
[TBL] [Abstract][Full Text] [Related]
40. Leveraging big data of immune checkpoint blockade response identifies novel potential targets.
Bareche Y; Kelly D; Abbas-Aghababazadeh F; Nakano M; Esfahani PN; Tkachuk D; Mohammad H; Samstein R; Lee CH; Morris LGT; Bedard PL; Haibe-Kains B; Stagg J
Ann Oncol; 2022 Dec; 33(12):1304-1317. PubMed ID: 36055464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
